
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is attractive because its core commercial engines are showing durable demand and meaningful operating leverage, even if 3Q/26 revenue of $101.9MM missed estimates due to timing-related issues rather than weakening fundamentals. FUROSCIX is transitioning rapidly to ReadyFlow, with ~75% of shipments converted by late October and management expecting 90%+ of scripts in Q4, while Afrezza’s pediatric launch has already lifted TRx ~17% q/q and more than doubled pediatric prescriptions. Tyvaso DPI royalties added $37.5MM in 3Q/26, CVR overhang has been removed, and management expects Q4/26 profitability and annual profitability in 2027 without needing to raise capital.
Bears say
MannKind is viewed negatively because its valuation depends heavily on Tyvaso DPI royalties and collaboration revenue that could be pressured if UTHR launches a competing SMI treprostinil device in 2027, while the company has limited control over partner execution. Commercial diversification also looks fragile: Afrezza’s pediatric launch is early, FUROSCIX still has a short sales history, and 2026E revenue sits below management’s $110M–$120M target, suggesting slower-than-expected uptake could limit growth. Cost discipline is deteriorating as SG&A rose 111% year over year to $61.4MM versus estimates, R&D fell to $14.4MM due to study discontinuations, and adjusted net income was a $3.6MM loss, underscoring execution and pipeline risk.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MannKind (MNKD) Forecast
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares